YouTube · Q2 2026 · 2026-08-07
HLN · NYSE
Haleon plc
Drug Manufacturers - Specialty & Generic · United Kingdom
USD 9.28-0.9% daily changeQuote 2026-09-18 · USD
- Market cap (USD)
- US$40.81B
- Trailing P/E
- 19.33x
- Forward P/E
- 14.87x
- Quarterly revenue growth
- 2.2%
- Trailing net margin
- 14.6%
- Indicated dividend yield
- 2.2%
Snapshot 2026-09-20 · Latest financial period 2026-06-30 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.
Company background
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc has a collaboration agreement with Microsoft to scale digital, data and AI capabilities across the business and accelerate delivery of its global win as one strategy. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
Company websiteH1 2026
Go beyond the headline.
Haleon (HLN): Margins Up, Buyback Done — And Growth That Missed Its Own Target Again
Published 2026-08-01
Comparable businesses
HLN peer comparison
Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.
| Metric | HLNHaleon plcSnapshot 2026-09-20Financial period: 2026-06-30 | ZTSZoetis Inc.Snapshot 2026-09-20Financial period: 2026-06-30 | TAKTakeda Pharmaceutical Company LimitedSnapshot 2026-09-20Financial period: 2026-06-30 | Peer medianSimilar-size peers only |
|---|---|---|---|---|
| Market capMarket value, converted to USD | US$40.81B | US$29.50B | US$60.39B | US$44.95Bn=2 |
| Forward P/EProvider forward earnings estimate | 14.87x | 10.93x | 35.68x | 23.31xn=2 |
| EV / EBITDAEnterprise value / trailing EBITDA | — | 9.12x | — | — |
| Revenue growthLatest quarter vs prior-year quarter | 2.2% | -0.2% | 10.2% | 5.0%n=2 |
| Operating marginLatest reported quarter | 23.9% | 40.7% | 16.4% | 28.6%n=2 |
| Free cash flow yieldTrailing cash flow / market cap | — | 6.8% | — | — |
| Net debt / EBITDANet debt / trailing EBITDA | 2.61x | 1.86x | 4.06x | 2.96xn=2 |
| Debt / equityTotal debt / positive book equity | 0.50x | — | 0.73x | — |
| Trailing P/ETrailing twelve-month earnings | 19.33x | 11.65x | — | — |
| Price / bookPrice / positive book equity per share | 1.88x | — | 1.21x | — |
| EV / salesEnterprise value / trailing revenue | — | 3.89x | — | — |
| Earnings growthLatest quarter vs prior-year quarter | -4.5% | 1.2% | -9.8% | -4.3%n=2 |
| Gross marginTrailing twelve months | 65.6% | 71.7% | 64.5% | 68.1%n=2 |
| Net marginTrailing twelve months | 14.6% | 27.7% | -3.5% | 12.1%n=2 |
| Return on equityProvider trailing return; positive equity only | 10.1% | — | -2.3% | — |
| Free cash flow marginTrailing free cash flow / revenue | 16.2% | 21.2% | 11.7% | 16.4%n=2 |
| Dividend yieldIndicated annual dividend / price | 2.2% | 3.0% | 3.3% | 3.1%n=2 |
| Earnings payoutProvider trailing dividend payout | 39.5% | 33.6% | 80.0% | 56.8%n=2 |
| Current ratioCurrent assets / current liabilities | 0.69x | 3.08x | 1.14x | 2.11xn=2 |
| BetaProvider historical market sensitivity | 0.24 | 0.73 | 0.10 | 0.41n=2 |
YouTube · Q2 2026 · 2026-08-07
Takeda Pharmaceutical Company Limited (TAK)
Similar size · 1.48x market cap
Drug Manufacturers - Specialty & Generic
YouTube · Q1 FY2026 · 2026-07-30
Comparison methodology & limitations
Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.
Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.
Reported performance
Financial trends
Periods are grouped by their ending calendar year or quarter, not identical fiscal calendars. Exact period-end dates appear in tooltips and reported figures. When reporting currencies differ and a recent captured FX rate is available, money and EPS are normalized to USD for comparison. This is not a historical FX restatement. Gaps are not estimated.
Financial statements load separately from the research page.
Source: . Window ends at the latest available reporting period.
Revenue
Reported figures
Financial data & calculation notes
Standalone charts use the stated reporting currency. When a chart comparison spans currencies, money and EPS can be normalized to USD using a recent captured FX snapshot; this is for comparison only, not a historical FX restatement. Stock-based compensation is noncash. Free cash flow is operating cash flow less capital spending, which may include capitalized software. Missing metrics are not estimated or assumed to be zero. Banking and insurance ratios require industry-specific interpretation. Latest restatements may differ from figures in older episodes.
Market context
Valuation & price history
Adjusted closing price
Price history loads separately.
Price figures
Earnings-multiple scenario
Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.
Starting assumptions, when available, use provider forward estimates as of 2026-09-20. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.
THE RESEARCH RECORD
Research history for HLN
H1 20262026-08-01
Haleon (HLN): Margins Up, Buyback Done — And Growth That Missed Its Own Target Again
Presentation · 2026-08-01 · YouTube